Press Releases

Date	Title
November 7, 2019	Corcept Therapeutics Announces Third quarter 2019 Financial Results and provides corporate update
October 31, 2019	Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
September 18, 2019	Corcept Therapeutics Appoints Kimberly Park to Board of Directors
August 28, 2019	Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome
August 1, 2019	Corcept Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update
July 25, 2019	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
May 28, 2019	Corcept Therapeutics to Present Data from Phase 1/2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Solid Tumors at the American Society of Clinical Oncology Annual Meeting
May 9, 2019	Corcept Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 3, 2019	Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
May 2, 2019	European Medicines Agency Recommends Orphan Drug Designation for Relacorilant to Treat Patients with Cushing’s Syndrome